Baltimore, MD (3/22/2023) — BC3 Technologies, a privately held medical device company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SEAL Hemostatic ...
The doubling of market valuation from $1.45 billion to $3.20 billion by 2033 represents more than numerical growth; it signals a fundamental evolution in surgical and emergency medicine practices. The ...
First look: The speed at which blood loss can become fatal has long challenged both military medics and trauma surgeons. Now, researchers at the Korea Advanced Institute of Science and Technology ...
Market valued at $1.45B in 2024 grows at 10.4% CAGR driven by biocompatible hemostatic solutions in surgical and trauma care settings. The shift toward nature-derived hemostatic solutions reflects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results